APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pharmacogenomics Technology (Theranostics & CDx)

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Pharmacogenomics Technology (Theranostics & CDx) Market Analysis and Forecast 2026-2032

29 December 2025192 pages

Choose your research edition.

Industry ResearchPharmacogenomics Technology (Theranostics & CDx) Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Pharmacogenomics Technology (Theranostics & CDx) Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Pharmacogenomics Technology (Theranostics & CDx) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pharmacogenomics Technology (Theranostics & CDx) Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Pharmacogenomics Technology (Theranostics & CDx) Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

Global Pharmacogenomics Technology (Theranostics & CDx) key players include Illumina, F. Hoffmann-La Roche, Agilent, Abbott, Thermo Fisher Scientific etc. Global top three players hold a share over 65%. North America is the largest market, with a share about 40%, followed by Europe and China, both have a share about 40 percent.

Report Includes

This report presents an overview of global market for Pharmacogenomics Technology (Theranostics & CDx), market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

Read the full market overview

This report researches the key producers of Pharmacogenomics Technology (Theranostics & CDx), also provides the revenue of main regions and countries. Of the upcoming market potential for Pharmacogenomics Technology (Theranostics & CDx), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Pharmacogenomics Technology (Theranostics & CDx) revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Pharmacogenomics Technology (Theranostics & CDx) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Pharmacogenomics Technology (Theranostics & CDx) revenue, projected growth trends, production technology, application and end-user industry.

Pharmacogenomics Technology (Theranostics & CDx) Segment by Company

Illumina

F. Hoffmann-La Roche

Agilent

Abbott

Thermo Fisher Scientific

Qiagen

Guardant Health

MGI Tech

Amoy Diagnostics

BGI Group

Pharmacogenomics Technology (Theranostics & CDx) Segment by Type

Instruments

Reagents and Consumables

Other

Pharmacogenomics Technology (Theranostics & CDx) Segment by Application

Tumour

Diabetes

Mental Illness

Cardiovascular Disease

Other

Pharmacogenomics Technology (Theranostics & CDx) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pharmacogenomics Technology (Theranostics & CDx) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pharmacogenomics Technology (Theranostics & CDx) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pharmacogenomics Technology (Theranostics & CDx).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Pharmacogenomics Technology (Theranostics & CDx) in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Pharmacogenomics Technology (Theranostics & CDx) company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Pharmacogenomics Technology (Theranostics & CDx) revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Instruments Major Player Table 3. Reagents and Consumables Major Player Table 4. Other Major Player Table 5. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Tumour Major Player Table 7. Diabetes Major Player Table 8. Mental Illness Major Player Table 9. Cardiovascular Disease Major Player Table 10. Other Major Player Table 11. Pharmacogenomics Technology (Theranostics & CDx) Industry Trends Table 12. Pharmacogenomics Technology (Theranostics & CDx) Industry Drivers Table 13. Pharmacogenomics Technology (Theranostics & CDx) Industry Opportunities and Challenges Table 14. Pharmacogenomics Technology (Theranostics & CDx) Industry Restraints Table 15. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 16. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region (2021-2026) & (US$ Million) Table 17. Global Pharmacogenomics Technology (Theranostics & CDx) Market Share by Region (2021-2026) Table 18. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region (2027-2032) & (US$ Million) Table 19. Global Pharmacogenomics Technology (Theranostics & CDx) Market Share by Region (2027-2032) Table 20. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue by Players (US$ Million) & (2021-2026) Table 21. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Players (2021-2026) Table 22. Global Pharmacogenomics Technology (Theranostics & CDx) Key Players Ranking, 2024 VS 2025 VS 2026 Table 23. Global Pharmacogenomics Technology (Theranostics & CDx) Key Players Headquarters & Area Served Table 24. Global Pharmacogenomics Technology (Theranostics & CDx) Players, Product Type & Application Table 25. Global Pharmacogenomics Technology (Theranostics & CDx) Players Establishment Date Table 26. Global Players Market Concentration Ratio (CR5 and HHI) Table 27. Global Pharmacogenomics Technology (Theranostics & CDx) by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 28. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2021-2026) & (US$ Million) Table 30. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2027-2032) & (US$ Million) Table 31. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Type (2021-2026) Table 32. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Type (2027-2032) Table 33. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2021-2026) & (US$ Million) Table 35. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2027-2032) & (US$ Million) Table 36. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Application (2021-2026) Table 37. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Application (2027-2032) Table 38. Illumina Company Information Table 39. Illumina Business Overview Table 40. Illumina Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. Illumina Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio Table 42. Illumina Recent Development Table 43. F. Hoffmann-La Roche Company Information Table 44. F. Hoffmann-La Roche Business Overview Table 45. F. Hoffmann-La Roche Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. F. Hoffmann-La Roche Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio Table 47. F. Hoffmann-La Roche Recent Development Table 48. Agilent Company Information Table 49. Agilent Business Overview Table 50. Agilent Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. Agilent Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio Table 52. Agilent Recent Development Table 53. Abbott Company Information Table 54. Abbott Business Overview Table 55. Abbott Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. Abbott Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio Table 57. Abbott Recent Development Table 58. Thermo Fisher Scientific Company Information Table 59. Thermo Fisher Scientific Business Overview Table 60. Thermo Fisher Scientific Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 61. Thermo Fisher Scientific Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio Table 62. Thermo Fisher Scientific Recent Development Table 63. Qiagen Company Information Table 64. Qiagen Business Overview Table 65. Qiagen Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 66. Qiagen Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio Table 67. Qiagen Recent Development Table 68. Guardant Health Company Information Table 69. Guardant Health Business Overview Table 70. Guardant Health Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 71. Guardant Health Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio Table 72. Guardant Health Recent Development Table 73. MGI Tech Company Information Table 74. MGI Tech Business Overview Table 75. MGI Tech Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 76. MGI Tech Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio Table 77. MGI Tech Recent Development Table 78. Amoy Diagnostics Company Information Table 79. Amoy Diagnostics Business Overview Table 80. Amoy Diagnostics Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 81. Amoy Diagnostics Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio Table 82. Amoy Diagnostics Recent Development Table 83. BGI Group Company Information Table 84. BGI Group Business Overview Table 85. BGI Group Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 86. BGI Group Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio Table 87. BGI Group Recent Development Table 88. North America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2021-2026) & (US$ Million) Table 89. North America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2027-2032) & (US$ Million) Table 90. North America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2021-2026) & (US$ Million) Table 91. North America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2027-2032) & (US$ Million) Table 92. North America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 93. North America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2021-2026) & (US$ Million) Table 94. North America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (US$ Million) & (2027-2032) Table 95. Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2021-2026) & (US$ Million) Table 96. Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2027-2032) & (US$ Million) Table 97. Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2021-2026) & (US$ Million) Table 98. Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2027-2032) & (US$ Million) Table 99. Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 100. Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2021-2026) & (US$ Million) Table 101. Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (US$ Million) & (2027-2032) Table 102. China Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2021-2026) & (US$ Million) Table 103. China Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2027-2032) & (US$ Million) Table 104. China Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2021-2026) & (US$ Million) Table 105. China Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2027-2032) & (US$ Million) Table 106. Asia Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2021-2026) & (US$ Million) Table 107. Asia Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2027-2032) & (US$ Million) Table 108. Asia Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2021-2026) & (US$ Million) Table 109. Asia Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2027-2032) & (US$ Million) Table 110. Asia Pharmacogenomics Technology (Theranostics & CDx) Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 111. Asia Pharmacogenomics Technology (Theranostics & CDx) Revenue by Region (US$ Million) & (2021-2026) Table 112. Asia Pharmacogenomics Technology (Theranostics & CDx) Revenue by Region (US$ Million) & (2027-2032) Table 113. SAMEA Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2021-2026) & (US$ Million) Table 114. SAMEA Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2027-2032) & (US$ Million) Table 115. SAMEA Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2021-2026) & (US$ Million) Table 116. SAMEA Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2027-2032) & (US$ Million) Table 117. SAMEA Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 118. SAMEA Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2021-2026) & (US$ Million) Table 119. SAMEA Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (US$ Million) & (2027-2032) Table 120. Research Programs/Design for This Report Table 121. Authors List of This Report Table 122. Secondary Sources Table 123. Primary Sources List of Figures Figure 1. Pharmacogenomics Technology (Theranostics & CDx) Image Figure 2. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Share 2021 VS 2025 VS 2032 Figure 4. Instruments Image Figure 5. Reagents and Consumables Image Figure 6. Other Image Figure 7. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Share 2021 VS 2025 VS 2032 Figure 9. Tumour Image Figure 10. Diabetes Image Figure 11. Mental Illness Image Figure 12. Cardiovascular Disease Image Figure 13. Other Image Figure 14. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size (US$ Million) & (2021-2032) Figure 15. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Pharmacogenomics Technology (Theranostics & CDx) Market Share by Region: 2021 VS 2025 VS 2032 Figure 17. Global Pharmacogenomics Technology (Theranostics & CDx) Players Revenue Share Top 10 and Top 5 in 2025 Figure 18. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Type (2021-2032) Figure 22. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 24. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Application (2021-2032) Figure 25. North America Pharmacogenomics Technology (Theranostics & CDx) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 26. North America Pharmacogenomics Technology (Theranostics & CDx) Revenue Share by Type (2021-2032) Figure 27. North America Pharmacogenomics Technology (Theranostics & CDx) Revenue Share by Application (2021-2032) Figure 28. North America Pharmacogenomics Technology (Theranostics & CDx) Revenue Share by Country (2021-2032) Figure 29. United States Pharmacogenomics Technology (Theranostics & CDx) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Canada Pharmacogenomics Technology (Theranostics & CDx) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Mexico Pharmacogenomics Technology (Theranostics & CDx) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 33. Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue Share by Type (2021-2032) Figure 34. Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue Share by Application (2021-2032) Figure 35. Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue Share by Country (2021-2032) Figure 36. Germany Pharmacogenomics Technology (Theranostics & CDx) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. France Pharmacogenomics Technology (Theranostics & CDx) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. U.K. Pharmacogenomics Technology (Theranostics & CDx) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Italy Pharmacogenomics Technology (Theranostics & CDx) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Spain Pharmacogenomics Technology (Theranostics & CDx) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Russia Pharmacogenomics Technology (Theranostics & CDx) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Netherlands Pharmacogenomics Technology (Theranostics & CDx) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Nordic Countries Pharmacogenomics Technology (Theranostics & CDx) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. China Pharmacogenomics Technology (Theranostics & CDx) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. China Pharmacogenomics Technology (Theranostics & CDx) Revenue Share by Type (2021-2032) Figure 46. China Pharmacogenomics Technology (Theranostics & CDx) Revenue Share by Application (2021-2032) Figure 47. Asia Pharmacogenomics Technology (Theranostics & CDx) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. Asia Pharmacogenomics Technology (Theranostics & CDx) Revenue Share by Type (2021-2032) Figure 49. Asia Pharmacogenomics Technology (Theranostics & CDx) Revenue Share by Application (2021-2032) Figure 50. Asia Pharmacogenomics Technology (Theranostics & CDx) Revenue Share by Region (2021-2032) Figure 51. Japan Pharmacogenomics Technology (Theranostics & CDx) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. South Korea Pharmacogenomics Technology (Theranostics & CDx) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. India Pharmacogenomics Technology (Theranostics & CDx) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Australia Pharmacogenomics Technology (Theranostics & CDx) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Taiwan Pharmacogenomics Technology (Theranostics & CDx) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Southeast Asia Pharmacogenomics Technology (Theranostics & CDx) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. SAMEA Pharmacogenomics Technology (Theranostics & CDx) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 58. SAMEA Pharmacogenomics Technology (Theranostics & CDx) Revenue Share by Type (2021-2032) Figure 59. SAMEA Pharmacogenomics Technology (Theranostics & CDx) Revenue Share by Application (2021-2032) Figure 60. SAMEA Pharmacogenomics Technology (Theranostics & CDx) Revenue Share by Country (2021-2032) Figure 61. Brazil Pharmacogenomics Technology (Theranostics & CDx) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Argentina Pharmacogenomics Technology (Theranostics & CDx) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Chile Pharmacogenomics Technology (Theranostics & CDx) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Colombia Pharmacogenomics Technology (Theranostics & CDx) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Peru Pharmacogenomics Technology (Theranostics & CDx) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Saudi Arabia Pharmacogenomics Technology (Theranostics & CDx) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Israel Pharmacogenomics Technology (Theranostics & CDx) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. UAE Pharmacogenomics Technology (Theranostics & CDx) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Turkey Pharmacogenomics Technology (Theranostics & CDx) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Iran Pharmacogenomics Technology (Theranostics & CDx) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Egypt Pharmacogenomics Technology (Theranostics & CDx) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Instruments
  • Reagents and Consumables
  • Other
Applications
  • Tumour
  • Diabetes
  • Mental Illness
  • Cardiovascular Disease
  • Other
Companies covered
  • Illumina
  • F. Hoffmann-La Roche
  • Agilent
  • Abbott
  • Thermo Fisher Scientific
  • Qiagen
  • Guardant Health
  • MGI Tech
  • Amoy Diagnostics
  • BGI Group

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Pharmacogenomics Technology (Theranostics & CDx) Market by Type
  3. 1.2.1 Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Instruments
  5. 1.2.3 Reagents and Consumables
  6. 1.2.4 Other
  7. 1.3 Pharmacogenomics Technology (Theranostics & CDx) Market by Application
  8. 1.3.1 Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Tumour
  10. 1.3.3 Diabetes
  11. 1.3.4 Mental Illness
  12. 1.3.5 Cardiovascular Disease
  13. 1.3.6 Other
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Pharmacogenomics Technology (Theranostics & CDx) Market Dynamics
  1. 2.1 Pharmacogenomics Technology (Theranostics & CDx) Industry Trends
  2. 2.2 Pharmacogenomics Technology (Theranostics & CDx) Industry Drivers
  3. 2.3 Pharmacogenomics Technology (Theranostics & CDx) Industry Opportunities and Challenges
  4. 2.4 Pharmacogenomics Technology (Theranostics & CDx) Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Pharmacogenomics Technology (Theranostics & CDx) Market Perspective (2021-2032)
  2. 3.2 Global Pharmacogenomics Technology (Theranostics & CDx) Growth Trends by Region
  3. 3.2.1 Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region (2021-2026)
  5. 3.2.3 Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Pharmacogenomics Technology (Theranostics & CDx) Revenue by Players
  2. 4.1.1 Global Pharmacogenomics Technology (Theranostics & CDx) Revenue by Players (2021-2026)
  3. 4.1.2 Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Pharmacogenomics Technology (Theranostics & CDx) Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Pharmacogenomics Technology (Theranostics & CDx) Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Pharmacogenomics Technology (Theranostics & CDx) Key Players Headquarters & Area Served
  7. 4.4 Global Pharmacogenomics Technology (Theranostics & CDx) Players, Product Type & Application
  8. 4.5 Global Pharmacogenomics Technology (Theranostics & CDx) Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Pharmacogenomics Technology (Theranostics & CDx) Market CR5 and HHI
  11. 4.6.3 2025 Pharmacogenomics Technology (Theranostics & CDx) Tier 1, Tier 2, and Tier 3
5 Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type
  1. 5.1 Global Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2021-2032)
  3. 5.3 Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Type (2021-2032)
6 Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application
  1. 6.1 Global Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2021-2032)
  3. 6.3 Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Illumina
  2. 7.1.1 Illumina Company Information
  3. 7.1.2 Illumina Business Overview
  4. 7.1.3 Illumina Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Illumina Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
  6. 7.1.5 Illumina Recent Developments
  7. 7.2 F. Hoffmann-La Roche
  8. 7.2.1 F. Hoffmann-La Roche Company Information
  9. 7.2.2 F. Hoffmann-La Roche Business Overview
  10. 7.2.3 F. Hoffmann-La Roche Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (2021-2026)
  11. 7.2.4 F. Hoffmann-La Roche Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
  12. 7.2.5 F. Hoffmann-La Roche Recent Developments
  13. 7.3 Agilent
  14. 7.3.1 Agilent Company Information
  15. 7.3.2 Agilent Business Overview
  16. 7.3.3 Agilent Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Agilent Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
  18. 7.3.5 Agilent Recent Developments
  19. 7.4 Abbott
  20. 7.4.1 Abbott Company Information
  21. 7.4.2 Abbott Business Overview
  22. 7.4.3 Abbott Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Abbott Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
  24. 7.4.5 Abbott Recent Developments
  25. 7.5 Thermo Fisher Scientific
  26. 7.5.1 Thermo Fisher Scientific Company Information
  27. 7.5.2 Thermo Fisher Scientific Business Overview
  28. 7.5.3 Thermo Fisher Scientific Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Thermo Fisher Scientific Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
  30. 7.5.5 Thermo Fisher Scientific Recent Developments
  31. 7.6 Qiagen
  32. 7.6.1 Qiagen Company Information
  33. 7.6.2 Qiagen Business Overview
  34. 7.6.3 Qiagen Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Qiagen Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
  36. 7.6.5 Qiagen Recent Developments
  37. 7.7 Guardant Health
  38. 7.7.1 Guardant Health Company Information
  39. 7.7.2 Guardant Health Business Overview
  40. 7.7.3 Guardant Health Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Guardant Health Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
  42. 7.7.5 Guardant Health Recent Developments
  43. 7.8 MGI Tech
  44. 7.8.1 MGI Tech Company Information
  45. 7.8.2 MGI Tech Business Overview
  46. 7.8.3 MGI Tech Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (2021-2026)
  47. 7.8.4 MGI Tech Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
  48. 7.8.5 MGI Tech Recent Developments
  49. 7.9 Amoy Diagnostics
  50. 7.9.1 Amoy Diagnostics Company Information
  51. 7.9.2 Amoy Diagnostics Business Overview
  52. 7.9.3 Amoy Diagnostics Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Amoy Diagnostics Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
  54. 7.9.5 Amoy Diagnostics Recent Developments
  55. 7.10 BGI Group
  56. 7.10.1 BGI Group Company Information
  57. 7.10.2 BGI Group Business Overview
  58. 7.10.3 BGI Group Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (2021-2026)
  59. 7.10.4 BGI Group Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
  60. 7.10.5 BGI Group Recent Developments
8 North America
  1. 8.1 North America Pharmacogenomics Technology (Theranostics & CDx) Revenue (2021-2032)
  2. 8.2 North America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2021-2032)
  3. 8.2.1 North America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2021-2026)
  4. 8.2.2 North America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2027-2032)
  5. 8.3 North America Pharmacogenomics Technology (Theranostics & CDx) Revenue Share by Type (2021-2032)
  6. 8.4 North America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2021-2032)
  7. 8.4.1 North America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2021-2026)
  8. 8.4.2 North America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2027-2032)
  9. 8.5 North America Pharmacogenomics Technology (Theranostics & CDx) Revenue Share by Application (2021-2032)
  10. 8.6 North America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country
  11. 8.6.1 North America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2021-2026)
  13. 8.6.3 North America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue (2021-2032)
  2. 9.2 Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2021-2032)
  3. 9.2.1 Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2021-2026)
  4. 9.2.2 Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2027-2032)
  5. 9.3 Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue Share by Type (2021-2032)
  6. 9.4 Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2021-2032)
  7. 9.4.1 Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2021-2026)
  8. 9.4.2 Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2027-2032)
  9. 9.5 Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue Share by Application (2021-2032)
  10. 9.6 Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country
  11. 9.6.1 Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2021-2026)
  13. 9.6.3 Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Pharmacogenomics Technology (Theranostics & CDx) Revenue (2021-2032)
  2. 10.2 China Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2021-2032)
  3. 10.2.1 China Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2021-2026)
  4. 10.2.2 China Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2027-2032)
  5. 10.3 China Pharmacogenomics Technology (Theranostics & CDx) Revenue Share by Type (2021-2032)
  6. 10.4 China Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2021-2032)
  7. 10.4.1 China Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2021-2026)
  8. 10.4.2 China Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2027-2032)
  9. 10.5 China Pharmacogenomics Technology (Theranostics & CDx) Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Pharmacogenomics Technology (Theranostics & CDx) Revenue (2021-2032)
  2. 11.2 Asia Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2021-2032)
  3. 11.2.1 Asia Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2021-2026)
  4. 11.2.2 Asia Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2027-2032)
  5. 11.3 Asia Pharmacogenomics Technology (Theranostics & CDx) Revenue Share by Type (2021-2032)
  6. 11.4 Asia Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2021-2032)
  7. 11.4.1 Asia Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2021-2026)
  8. 11.4.2 Asia Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2027-2032)
  9. 11.5 Asia Pharmacogenomics Technology (Theranostics & CDx) Revenue Share by Application (2021-2032)
  10. 11.6 Asia Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country
  11. 11.6.1 Asia Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2021-2026)
  13. 11.6.3 Asia Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Pharmacogenomics Technology (Theranostics & CDx) Revenue (2021-2032)
  2. 12.2 SAMEA Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2027-2032)
  5. 12.3 SAMEA Pharmacogenomics Technology (Theranostics & CDx) Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2027-2032)
  9. 12.5 SAMEA Pharmacogenomics Technology (Theranostics & CDx) Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country
  11. 12.6.1 SAMEA Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst